Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry

被引：11

作者：

Al-Batran, Salah-Eddin ^{[1
,3
]}

Hofheinz, Ralf-Dieter ^{[2
]}

Reichart, Alexander ^{[1
,3
]}

Pauligk, Claudia ^{[3
]}

Schoenherr, Caroline ^{[3
]}

Schlag, Rudolf ^{[4
]}

Siegler, Gabriele ^{[5
]}

Doerfel, Steffen ^{[6
]}

Koenigsmann, Michael ^{[7
]}

Zahn, Mark-Oliver ^{[8
]}

Schubert, Joerg ^{[9
]}

Aldaoud, Ali ^{[10
]}

Hoeffkes, Heinz-Gert ^{[11
,12
]}

Schulz, Holger ^{[13
]}

Hahn, Lars ^{[14
]}

Uhlig, Jens ^{[15
]}

Blau, Wolfgang ^{[16
]}

Stauch, Martina ^{[17
]}

Weniger, Joerg ^{[18
]}

Wolf, Martin ^{[19
]}

Jacobasch, Lutz ^{[20
]}

Bildat, Stephan ^{[21
,22
]}

Wehmeyer, Juergen ^{[23
]}

Homann, Nils ^{[24
]}

Trojan, Joerg ^{[25
]}

Waidmann, Oliver ^{[25
]}

Fietz, Thomas ^{[26
]}

Feustel, Hans-Peter ^{[27
]}

Groschek, Matthias ^{[28
]}

Wierecky, Jan ^{[29
]}

Waibel, Karin ^{[30
]}

Mahlmann, Stefan ^{[31
]}

Schwindel, Uwe ^{[32
]}

Peters, Uwe ^{[33
]}

Schuch, Gunter ^{[34
]}

Pink, Daniel ^{[35
,36
]}

Eschenburg, Henning ^{[37
]}

Woerns, Marcus-A. ^{[38
]}

Harich, Hans-Detlev ^{[39
]}

von Weikersthal, Ludwig Fischer ^{[40
]}

Daessler, Klaus-Ulrich ^{[41
]}

Behringer, Dirk M. ^{[42
]}

Messmann, Helmut ^{[43
]}

Kretzschmar, Albrecht ^{[44
]}

Gallmeier, Eike ^{[45
]}

Forstbauer, Helmut ^{[46
]}

Kunzmann, Volker ^{[47
]}

Papke, Jens ^{[48
]}

Buechner-Steudel, Petra ^{[49
]}

Vehling-Kaiser, Ursula ^{[50
]}

机构：

[1] UCT Univ Canc Ctr, Krankenhaus Nordwest, Frankfurt, Germany

[2] Univ Med Mannheim, Interdisziplinares Tumorzentrum, Mannheim, Germany

[3] Krankenhaus NW Frankfurt, Inst Klin Krebsforsch IKF GmbH, Frankfurt, Germany

[4] Gemeinschaftspraxis Schlag Schottker, Wurzburg, Germany

[5] Klinikum Nurnberg PMU, Nurnberg, Germany

[6] Onkozentrum Dresden, Dresden, Germany

[7] MediProjekt GbR, Hannover, Germany

[8] MVZ Onkol Kooperat Harz, Goslar, Germany

[9] Elblandklinikum Riesa, Riesa, Germany

[10] HELIOS Pk Klinikum, Pankreaszentrum Leipzig, Leipzig, Germany

[11] Univ Med Marburg, Klinikum Fulda, Fulda, Germany

[12] MVZ Osthessen GmbH, Fulda, Germany

[13] Pioh Frechen Koln Praxis Internist Onkol & Hamato, Frechen, Germany

[14] Dokusan Gesell Med Studien GmbH & Co KG, Herne, Germany

[15] Hamatol Onkol Schwerpunktpraxis, Naunhof, Germany

[16] Univ Klinikum Giessen & Marburg, Med Klin 4 5, Giessen, Germany

[17] Schwerpunktpraxis Hamatol Onkol, Kronach, Germany

[18] Gemeinschaftspraxis Hamatol & Onkol Dres Wenige B, Erfurt, Germany

[19] Klinikum Kassel GmbH, Klin Hamatol & Onkol, Kassel, Germany

[20] Onkol Gemeinschaftspraxis Dr Med Lutz Jacobasch, Dresden, Germany

[21] Klinikum Herford, Med Klin 2, Herford, Germany

[22] Onkol Zentrum, MVZ Onkol, Herford, Germany

[23] Gemeinschaftspraxis Hamatol & Onkol, Munster, Germany

[24] Klinikum Wolfsburg, Med Klin 2, Wolfsburg, Germany

[25] Klinikum JW Goethe Univ Frankfurt, Frankfurt, Germany

[26] Schwerpunktpraxis Hamatol, Onkol & Gastroenterol Dres Banhardt Fietz Hertkor, Singen, Germany

[27] Onkol Schwerpunktpraxis Speyer, Speyer, Germany

[28] Clin Res Stolberg GmbH, Stolberg, Germany

[29] Schwerpunkt Hamatol Onkol & Palliativmed, Uberortliche Gemeinschaftspraxis, Hamburg, Germany

[30] Medius Kliniken gGmbH, Medius Klin Ostfildern Ruit, Ostfildern Ruit, Germany

[31] Westpfalz Klinikum GmbH, Kaiserslautern, Germany

[32] GPR Gesundheits & Pflegezentrum gGmbH, Med Klin 1, Russelsheim, Germany

[33] Ambulantes Tumorzentrum Spandau Dres Peters & Sae, Berlin, Germany

[34] Hamatol Onkol Praxis Altona HOPA, Hamburg, Germany

[35] Ernst Moritz Arndt Univ Greifswald, Klin & Poliklin Innere Med C, Hamatol & Onkol, Transplantationszentrum,Palliativmed, Greifswald, Germany

[36] HELIOS Klinikum Bad Saarow, Sarkomzentrum Berlin Brandenburg, Klin Hamatol Onkol & Palliativmed, Brandenburg, Germany

[37] Internist Gemeinschaftspraxis Dres, Gustrow, Germany

[38] Univ Med Mainz, Med Klin & Poliklin 1, Mainz, Germany

[39] Onkol Hof MVZ Dres Kasper Harich, Hof, Germany

[40] Gesundheitszentrum St Marien GmbH, Praxis Hamatol & Internist Onkol, Amberg, Germany

[41] Praxis Dipl Med Klaus Ulrich Dassler, Freital, Germany

[42] Augusta Kranken Anstalt gGmbH, Bochum, Germany

[43] Univ Klinikum Augsburg, Med Klin 3, Augsburg, Germany

[44] MVZ Mitte Onkol Schwerpunktpraxis, Leipzig, Germany

[45] Univ Klinikum Giessen & Marburg GmbH, Klin Innere Med, Marburg, Germany

[46] GOSPL Gesell Onkol Studien, Troisdorf, Germany

[47] Univ Klin Wurzburg, Zentrum Innere Med, Med Klin & Poliklin 2, Wurzburg, Germany

[48] Praxis Prof Dr Med Jens Papke, Neustadt, Germany

[49] Univ Klinikum Halle Saale, Klin & Poliklin Innere Med 1, Halle, Germany

[50] VK&K Studien GbR, Landshut, Germany

来源：

INTERNATIONAL JOURNAL OF CANCER | 2021年 / 148卷 / 06期

关键词：

chemotherapy; pancreatic cancer; PARAGON; QOLIXANE; quality of life; registry; PLUS GEMCITABINE; SURVIVAL; FOLFIRINOX; IMPACT; THERAPY; MPACT;

D O I：

10.1002/ijc.33336

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Few data exist on health-related quality of life (QoL) in patients with metastatic pancreatic cancer (mPC) receiving first-line chemotherapy (Awad L ZE, Mesbah M Boston, MA. Applying survival data methodology to analyze quality of life data, in Mesbah M, Cole BF, Ting Lee M-L (eds): Statistical Methods for Quality of Life Studies: Design, Measurements and Analysis. Kluwer Academic Publishers 2002). The QOLIXANE study is a prospective, noninterventional, multicenter substudy of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer (PARAGON) registry, which evaluated QoL in patients with mPC receiving first-line gemcitabine and nab-paclitaxel chemotherapy in real-life setting. QoL was prospectively measured via EORTC QLQ-C30 questionnaires at baseline and every month thereafter. Therapy and efficacy parameters were prospectively collected. Main objectives were the rate of patients without deterioration of Global Health Status/QoL (GHS/QoL) at 3 and 6 months. Six hundred patients were enrolled in 95 German study sites. Median progression-free survival was 5.9 months (95% confidence interval [CI], 5.2-6.3). Median overall survival (OS) was 8.9 months (95% CI, 7.9-10.2), while median time to deterioration of GHS/QoL was 4.7 months (95% CI, 4.0-5.6). With a baseline GHS/QoL score of 46 (SD, 22.8), baseline QoL of the patients was severely impaired, in most cases due to loss in role functioning and fatigue. In the Kaplan-Meier analysis, 61% and 41% of patients had maintained GHS/QoL after 3 and 6 months, respectively. However, in the QoL response analysis, 35% and 19% of patients had maintained (improved or stable) GHS/QoL after 3 and 6 months, respectively, while 14% and 9% had deteriorated GHS/QoL with the remaining patients being nonevaluable. In the Cox regression analysis, GHS/QoL scores strongly predicted survival with a hazard ratio of 0.86 (P < .0001). Patients with mPC have poor QoL at baseline that deteriorates within a median of 4.7 months. Treatment with gemcitabine and nab-paclitaxel is associated with maintained QoL in relevant proportions of patients. However, overall, results remain poor, reflecting the aggressive nature of the disease.

引用

页码：1478 / 1488

页数：11

共 50 条

[21] Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution
Quan, Qi
Wang, Yixing
Wang, Fenghua
Zhang, Dongsheng
Chen, Xiuxing
He, Wenzhuo
Zhang, Bei
Guo, Guifang
CURRENT ONCOLOGY, 2021, 28 (01) : 209 - 219
[22] Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores
Hwang, Inhwan
Kang, Jihoon
Ip, Hei Nga Natalie
Jeong, Jae Ho
Kim, Kyu-pyo
Chang, Heung-Moon
Yoo, Changhoon
Ryoo, Baek-Yeol
INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 584 - 590
[23] Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial
Charton, Emilie
Bachet, Jean-Baptiste
Hammel, Pascal
Desrame, Jerome
Chibaudel, Benoist
Cohen, Romain
Dcbourdcau, Philippe
Dauba, Jerome
Lecomte, Thierry
Seitz, Jean-Francois
Tournigand, Christophe
Aparicio, Thomas
Guerin-Meyer, Veronique
Taieb, Julien
Volet, Julien
Louvet, Christophe
Anota, Amelie
Bonnetain, Franck
CANCER MEDICINE, 2019, 8 (11): : 5079 - 5088
[24] Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice
Berta Laquente
Teresa Macarulla
Cristina Bugés
Marta Martín
Carlos García
Carles Pericay
Sandra Merino
Laura Visa
Teresa Martín
Manuela Pedraza
Beatriz Carnero
Raquel Guardeño
Helena Verdaguer
Alejandro Mut
David Vilanova
Adelaida García
BMC Palliative Care, 19
[25] Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice
Laquente, Berta
Macarulla, Teresa
Buges, Cristina
Martin, Marta
Garcia, Carlos
Pericay, Carles
Merino, Sandra
Visa, Laura
Martin, Teresa
Pedraza, Manuela
Carnero, Beatriz
Guardeno, Raquel
Verdaguer, Helena
Mut, Alejandro
Vilanova, David
Garcia, Adelaida
BMC PALLIATIVE CARE, 2020, 19 (01)
[26] Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
Steffen Ormanns
Michael Haas
Sibylle Baechmann
Annelore Altendorf-Hofmann
Anna Remold
Detlef Quietzsch
Michael R Clemens
Martin Bentz
Michael Geissler
Helmut Lambertz
Stephan Kruger
Thomas Kirchner
Volker Heinemann
Stefan Boeck
British Journal of Cancer, 2016, 115 : 1520 - 1529
[27] Efficacy of relative dose intensity of nab-paclitaxel for the short-term outcomes, survival, and quality of life in patients with advanced pancreatic cancer: a retrospective study
Lian, Lian
Shen, Xiao-Ming
Huang, Tie-Ao
Li, Da-Peng
Li, Xian-Min
Han, Shu-Guang
Xu, Xue-Fei
Ma, Chun-Tao
Zhou, Chong
TRANSLATIONAL CANCER RESEARCH, 2022, 11 (07) : 2310 - 2320
[28] The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients A Multicenter Real-Life Study
Akdeniz, Nadiye
Kaplan, Muhammet Ali
Inanc, Mevlude
Uncu, Dogan
Ergun, Yakup
Kucukoner, Mehmet
Demirci, Ayse
Sendur, Mehmet Ali Nahit
Besiroglu, Mehmet
Topcu, Atakan
Yerlikaya, Halis
Urakci, Zuhat
Kilickap, Saadettin
Isikdogan, Abdurrahman
PANCREAS, 2022, 51 (09) : 1153 - 1159
[29] Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores
Inhwan Hwang
Jihoon Kang
Hei Nga Natalie Ip
Jae Ho Jeong
Kyu-pyo Kim
Heung-Moon Chang
Changhoon Yoo
Baek-Yeol Ryoo
Investigational New Drugs, 2019, 37 : 584 - 590
[30] Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
Gourgou-Bourgade, Sophie
Bascoul-Mollevi, Caroline
Desseigne, Francoise
Ychou, Marc
Bouche, Olivier
Guimbaud, Rosine
Becouarn, Yves
Adenis, Antoine
Raoul, Jean-Luc
Boige, Valerie
Berille, Jocelyne
Conroy, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 23 - 29

← 1 2 3 4 5 →